U.S. FDA approves Bluebird bio’s gene therapy for a rare neurological disorder Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

​Bluebird said it anticipates commercial product will be available by the end of 2022 through a limited number of qualified treatment centers in the United States., ​Bluebird said it anticipates commercial product will be available by the end of 2022 through a limited number of qualified treatment centers in the United States., , Read More